Neurocognitive Changes

  • Jane H. CerhanEmail author
  • Alissa M. Butts
  • Michael W. Parsons
  • Paul D. Brown


Patients with cancer often experience cognitive changes, and this is even more common in patients with brain tumors. In this chapter, we review cognitive deficits associated with cancer and cancer treatments. We also discuss the impact of various radiotherapies on cognition, including approaches to cognitive sparing. Finally, the role of neuropsychological assessment in cancer care and research is reviewed, along with a case example.


Brain tumor Radiotherapy Cognition Neuropsychology Chemotherapy 


  1. 1.
    Li J, Bentzen SM, Li J, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64–70. Scholar
  2. 2.
    Farace E, Shaffrey ME. Relationship of neurocognitive impairment to QOL in malignant brain tumor patients (abstract). J Neuropsychiatry Clin Neurosci. 2000;13:1.Google Scholar
  3. 3.
    Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003;5:89–95. Scholar
  4. 4.
    Janelsins MC, Kesler SR, Ahles TA, et al. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26:102–13. Scholar
  5. 5.
    Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9. Scholar
  6. 6.
    Cimprich B. Attentional fatigue following breast cancer surgery. Res Nurs Health. 1992;15:199–207.CrossRefPubMedGoogle Scholar
  7. 7.
    Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56. Scholar
  8. 8.
    Cimprich B, Reuter-Lorenz P, Nelson J, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32:324–31. Scholar
  9. 9.
    Reuter-Lorenz P. New visions of the aging mind and brain. Trends Cogn Sci. 2002;6:394.CrossRefPubMedGoogle Scholar
  10. 10.
    Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86. Scholar
  11. 11.
    Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44. Scholar
  12. 12.
    Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol. 2003;26:273–9. Scholar
  13. 13.
    Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529–36. Scholar
  14. 14.
    Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157–65. Scholar
  15. 15.
    Sherman AM, Jaeckle K, Meyers CA. Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer. 2002;95:1311–6. Scholar
  16. 16.
    Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68. Scholar
  17. 17.
    Gerstenecker A, Nabors LB, Meneses K, et al. Cognition in patients with newly diagnosed brain metastasis: profiles and implications. J Neurooncol. 2014;120:179–85. Scholar
  18. 18.
    Tucha O, Smely C, Preier M, et al. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324–33. discussion 333-324CrossRefPubMedGoogle Scholar
  19. 19.
    Racine CA, Li J, Molinaro AM, et al. Neurocognitive function in newly diagnosed low-grade glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery. 2015;77:371–9.; discussion 379. Scholar
  20. 20.
    Derks J, Reijneveld JC, Douw L. Neural network alterations underlie cognitive deficits in brain tumor patients. Curr Opin Oncol. 2014;26:627–33. Scholar
  21. 21.
    Lee EQ. Nervous system metastases from systemic cancer. Continuum (Minneap Minn). 2015;21:415–28. Scholar
  22. 22.
    Kayl AE, Meyers CA. Does brain tumor histology influence cognitive function? Neuro Oncol. 2003;5:255–60. Scholar
  23. 23.
    Noll KR, Sullaway C, Ziu M, et al. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol. 2015;17:580–7. Scholar
  24. 24.
    Wefel JS, Noll KR, Rao G, et al. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol. 2016;18:1656–63. Scholar
  25. 25.
    Duffau H, Herbet G, Moritz-Gasser S. Toward a pluri-component, multimodal, and dynamic organization of the ventral semantic stream in humans: lessons from stimulation mapping in awake patients. Front Syst Neurosci. 2013;7:44. Scholar
  26. 26.
    Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82. Scholar
  27. 27.
    Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70. Scholar
  28. 28.
    Hodgson KD, Hutchinson AD, Wilson CJ, et al. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39:297–304. Scholar
  29. 29.
    Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33. Scholar
  30. 30.
    Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87. Scholar
  31. 31.
    Ono M, Ogilvie JM, Wilson JS, et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol. 2015;5:59. Scholar
  32. 32.
    Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89. Scholar
  33. 33.
    Lindner OC, Phillips B, McCabe MG, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28:726–40. Scholar
  34. 34.
    Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507. Scholar
  35. 35.
    Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742–5. Scholar
  36. 36.
    Dietrich J, Prust M, Kaiser J. Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 2015;309:224–32. Scholar
  37. 37.
    McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25. Scholar
  38. 38.
    Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8:88–91. Scholar
  39. 39.
    Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32:480–93. Scholar
  40. 40.
    Bruno J, Hosseini SM, Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis. 2012;48:329–38. Scholar
  41. 41.
    Horky LL, Gerbaudo VH, Zaitsev A, et al. Systemic chemotherapy decreases brain glucose metabolism. Ann Clin Transl Neurol. 2014;1:788–98. Scholar
  42. 42.
    McDonald BC, Conroy SK, Ahles TA, et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30:2500–8. Scholar
  43. 43.
    Besse B, Le Moulec S, Mazieres J, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated BRAIN metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21:1896–903. Scholar
  44. 44.
    Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9. Scholar
  45. 45.
    Centre Hospitalier Intercommunal Creteil (sponsor). Therapeutic strategies in patients with non-squamous non-small cell lung cancer with brain metastases (METAL2) ( identifier NCT02162537). 2017. Accessed 2017. Available at:
  46. 46.
    Ahluwalia MS, Chao ST, Parsons MW, et al. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases. J Neurooncol. 2015;124:485–91. Scholar
  47. 47.
    Brastianos PK, Carter SL, Santagata S, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164–77. Scholar
  48. 48.
    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9. Scholar
  49. 49.
    Brown PD, Cerhan JH. Same, better, or worse? Neurocognitive effects of radiotherapy for low-grade gliomas remain unknown. Lancet Neurol. 2009;8:779–81. Scholar
  50. 50.
    Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29:279–86. Scholar
  51. 51.
    Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557–8. Scholar
  52. 52.
    Makale MT, McDonald CR, Hattangadi-Gluth JA, et al. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol. 2017;13:52–64. Scholar
  53. 53.
    Wefel JS, Noll KR, Scheurer ME. Neurocognitive functioning and genetic variation in patients with primary brain tumours. Lancet Oncol. 2016;17:e97–e108. Scholar
  54. 54.
    Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment--from bench to bedside. Neuro Oncol. 2012;14(Suppl 4):iv37–44. CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Schultheiss TE, Stephens LC. Invited review: permanent radiation myelopathy. Br J Radiol. 1992;65:737–53. Scholar
  56. 56.
    Taphoorn MJB, Niël CG. Low-grade gliomas. In: Meyers CA, Perry JR, editors. Cognition and cancer. New York, NY: Cambridge University Press; 2008. p. 142.CrossRefGoogle Scholar
  57. 57.
    Onodera S, Aoyama H, Tha KK, et al. The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol. 2014;120:311–9. CrossRefPubMedGoogle Scholar
  58. 58.
    McDuff SG, Taich ZJ, Lawson JD, et al. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry. 2013;84:1384–91. Scholar
  59. 59.
    DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789–96.CrossRefPubMedGoogle Scholar
  60. 60.
    Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401–9. Scholar
  61. 61.
    Chang JE, Robins HI, Mehta MP. Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol. 2007;5:54–64.PubMedGoogle Scholar
  62. 62.
    Laack NN, Brown PD, Ivnik RJ, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a north central cancer treatment group prospective study. Int J Radiat Oncol Biol Phys. 2005;63:1175–83. Scholar
  63. 63.
    Steinvorth S, Wenz F, Wildermuth S, et al. Cognitive function in patients with cerebral arteriovenous malformations after radiosurgery: prospective long-term follow-up. Int J Radiat Oncol Biol Phys. 2002;54:1430–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy. Technol Cancer Res Treat. 2013;12:1–9. Scholar
  65. 65.
    Sherman JC, Colvin MK, Mancuso SM, et al. Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol. 2016;126:157–64.CrossRefPubMedGoogle Scholar
  66. 66.
    Marsh JC, Ziel GE, Diaz AZ, et al. Integral dose delivered to normal brain with conventional intensity-modulated radiotherapy (IMRT) and helical tomotherapy IMRT during partial brain radiotherapy for high-grade gliomas with and without selective sparing of the hippocampus, limbic circuit and neural stem cell compartment. J Med Imaging Radiat Oncol. 2013;57:378–83. Scholar
  67. 67.
    Gondi V, Tome WA, Mehta MP. Why avoid the hippocampus? A comprehensive review. Radiother Oncol. 2010;97:370–6. Scholar
  68. 68.
    Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2012;83:e487–93. Scholar
  69. 69.
    Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32:3810–6. Scholar
  70. 70.
    Tsai PF, Yang CC, Chuang CC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study. Radiat Oncol. 2015;10:253. Scholar
  71. 71.
    Day J, Zienius K, Gehring K, et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev. 2014;12:CD011335. Scholar
  72. 72.
    Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-oncol. 2013;15:1429–37. Scholar
  73. 73.
    Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522–7. Scholar
  74. 74.
    Gehring K, Patwardhan SY, Collins R, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol. 2012;107:165–74. Scholar
  75. 75.
    Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33:1653–9. Scholar
  76. 76.
    Burns TC, Awad AJ, Li MD, et al. Radiation-induced brain injury: low-hanging fruit for neuroregeneration. Neurosurg Focus. 2016;40:E3. Scholar
  77. 77.
    Locke DEC, Cerhan JH, Malec JF. Behavioral strategies and rehabilitation. In: Meyers CA, Perry JR, editors. Cognition and cancer. New York, NY: Cambridge University Press; 2008.Google Scholar
  78. 78.
    Locke DE, Cerhan JH, Wu W, et al. Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study. J Support Oncol. 2008;6:383–91.PubMedGoogle Scholar
  79. 79.
    Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol. 2009;27:3712–22. Scholar
  80. 80.
    Riggs L, Piscione J, Laughlin S, et al. Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. Neuro Oncol. 2017;19:440–50. Scholar
  81. 81.
    Treanor CJ, McMenamin UC, O'Neill RF, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database Syst Rev. 2016;8:CD011325. Scholar
  82. 82.
    Harvey PD. Clinical applications of neuropsychological assessment. Dialogues Clin Neurosci. 2012;14:91–9.PubMedPubMedCentralGoogle Scholar
  83. 83.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Litofsky NS, Farace E, Anderson F Jr, et al. Glioma outcomes project I. Depression in patients with high-grade glioma: results of the Glioma outcomes project. Neurosurgery. 2004;54:358–66. discussion 366-357CrossRefPubMedGoogle Scholar
  85. 85.
    Gehring K, Taphoorn MJ, Sitskoorn MM, et al. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. Neurooncol Pract. 2015;2:20–31. Scholar
  86. 86.
    Comijs HC, Deeg DJ, Dik MG, et al. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics. A 6-year follow-up study. J Affect Disord. 2002;72:157–65.CrossRefPubMedGoogle Scholar
  87. 87.
    Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology. 2010;24:573–80. Scholar
  88. 88.
    Brennan RL, editor. Educational measurement. 4th ed. Lanham, MD: Rowman & Littlefield Publishers; 2006.Google Scholar
  89. 89.
    Messick S. Validity of psychological assessment: validation of inferences from persons' responses and performances as scientific inquiry into score meaning. Am Psychol. 1995;50:741–9.CrossRefGoogle Scholar
  90. 90.
    Cronbach LJ. Test validation. In: Thorndike RL, editor. Educational measurement. 2nd ed. Washington, DC: American Council on Education; 1971. p. 443–507.Google Scholar
  91. 91.
    Bauer RM, Iverson GL, Cernich AN, et al. Computerized neuropsychological assessment devices: joint position paper of the American academy of clinical neuropsychology and the national academy of neuropsychology. Arch Clin Neuropsychol. 2012;27:362–73. Scholar
  92. 92.
    Downing SM, Haladyna TM, editors. Handbook of test development. Mahway, NJ: Lawrence Erlbaum Associates, Publishers; 2006.Google Scholar
  93. 93.
    American Educational Research Association, American Psychological Association, National Council on Measurement in Education. Standards for educational and psychological testing. Washington, DC: American Educational Research Association; 2014.Google Scholar
  94. 94.
    Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013;14:e396–406. Scholar
  95. 95.
    Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14:e407–16. Scholar
  96. 96.
    Brown PD, Buckner JC, Uhm JH, et al. The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro Oncol. 2003;5:161–7. Scholar
  97. 97.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Spreen O, Benton AL. Comparative studies of some psychological tests for cerebral damage. J Nerv Ment Dis. 1965;140:323–33.CrossRefPubMedGoogle Scholar
  99. 99.
    Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708. Scholar
  100. 100.
    Reitan RM. Trail making test: manual for administration and scoring. Reitan Neuropsychological Laboratory: South Tucson, AZ; 1992.Google Scholar
  101. 101.
    Brandt J. The Hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–42.CrossRefGoogle Scholar
  102. 102.
    Benton AL, Hamsher K. Multilingual aphasia examination. Manual of instructions. 2nd ed. Iowa City, IA: AJA Associates; 1989.Google Scholar
  103. 103.
    Joly F, Giffard B, Rigal O, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manag. 2015;50:830–41. Scholar
  104. 104.
    Wechsler D. The wechsler adult intelligence scale, 4th ed. (WAIS-IV). Pearson Assessment: San Antonio, TX; 2009.Google Scholar
  105. 105.
    Anastasi A, Urbina S. Psychologial testing. 7th ed. Pearson: New York, NY; 1997.Google Scholar
  106. 106.
    Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological assessment. 5th ed. Oxford, England, UK: Oxford University Press; 2012.Google Scholar
  107. 107.
    Attix DK, Story TJ, Chelune GJ, et al. The prediction of change: normative neuropsychological trajectories. Clin Neuropsychol. 2009;23:21–38. Scholar
  108. 108.
    Heilbronner RL, Sweet JJ, Attix DK, et al. Official position of the American Academy of clinical neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. Clin Neuropsychol. 2010;24:1267–78. Scholar
  109. 109.
    Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests. 3rd ed. Oxford, England, UK: Oxford University Press; 2006.Google Scholar
  110. 110.
    Crawford JR, Garthwaite PH, Denham AK, et al. Using regression equations built from summary data in the psychological assessment of the individual case: extension to multiple regression. Psychol Assess. 2012;24:801–14. Scholar
  111. 111.
    Hinton-Bayre AD. Deriving reliable change statistics from test-retest normative data: comparison of models and mathematical expressions. Arch Clin Neuropsychol. 2010;25:244–56. Scholar
  112. 112.
    Chelune GJ. Assessing reliable neuropsychological change. In: Franklin R, editor. Prediction in forensic and neuropsychology: new approaches to psychometrically sound assessment. Mahway, NJ: Lawrence Erlbaum Associates, Inc.; 2003.Google Scholar
  113. 113.
    Duff K. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol. 2012;27:248–61. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Jane H. Cerhan
    • 1
    Email author
  • Alissa M. Butts
    • 1
  • Michael W. Parsons
    • 2
  • Paul D. Brown
    • 3
  1. 1.Department of Psychiatry and PsychologyMayo ClinicRochesterUSA
  2. 2.Burkhardt Brain Tumor Center, Cleveland ClinicClevelandUSA
  3. 3.Department of Radiation OncologyMayo ClinicRochesterUSA

Personalised recommendations